DV
Dividend Vision

HELX — Franklin Genomic Advancements ETF

Franklin Genomic Advancements ETF (HELX)

HELX carries a 0.50% expense ratio. Its Distribution Safety Score™ is 50 (Caution). Total return is 70.3% over the past 6.5 years, 116.0 points behind SPY at 186.3%. Its deepest 1-year drawdown was 18.0%.

Franklin Genomic Advancements ETF is an exchange-traded fund that invests at least 80% of its net assets in equity securities of companies involved in genomic advancements, with a concentration in health care–related industries. The fund carries a very low distribution rate, pays distributions annually, and has an expense ratio of 0.50%.

HELX key facts

Distribution Safety Score™
50 · Caution
Issuer
Franklin Templeton
Asset type
ETF
Asset class
Equity
Inception date
02/25/2020
Expense ratio
0.50%
Distribution frequency
Annual
Trailing yield
0.35%
Last close
$40.50
AUM
$29,648,175
Average volume
1805.0
Ex-dividend date
12/30/2025
Payment date
01/08/2026
Beta
0.98
P/E ratio
34.3873